WIPO logo
모바일 | Deutsch | English | Español | Français | 日本語 | Português | Русский | 中文 | العربية |
PATENTSCOPE

국제 및 국내 특허문헌 검색
World Intellectual Property Organization
검색
 
열람
 
번역
 
옵션
 
뉴스
 
로그인
 
도움말
 
기계 번역
1. (WO2012112626) COMPOSITIONS, DEVICES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCERS
국제사무국에 기록된 최신 서지정보   

공개번호:    WO/2012/112626    국제출원번호:    PCT/US2012/025140
공개일: 23.08.2012 국제출원일: 14.02.2012
IPC:
A61K 38/05 (2006.01)
출원인: INTARCIA THERAPEUTICS, INC. [US/US]; 24650 Industrial Blvd Hayward, CA 94545 (US) (For All Designated States Except US).
LEUNG, Karling, Alice [US/US]; (US) (For US Only)
발명자: LEUNG, Karling, Alice; (US)
대리인: ELRIFI, Ivor, R.; MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO, P.C. One Financial Center Boston, MA 02111 (US)
우선권 정보:
61/443,628 16.02.2011 US
발명의 명칭: (EN) COMPOSITIONS, DEVICES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCERS
(FR) COMPOSITIONS, DISPOSITIFS ET PROCÉDÉS D'UTILISATION DE CELLES-CI DANS LE TRAITEMENT DES CANCERS
요약서: front page image
(EN)The use of GLP-1 receptor agonists, such as glucagon-like peptide- 1 (GLP-1) or exenatide, for the treatment of cancer is described. The GLP-1 receptor agonists are typically delivered using an implanted osmotic delivery device that provides for continuous delivery of the GLP-1 receptor agonist for at least one month. Additional beneficial agents, such as anticancer agents, can also be administered.
(FR)La présente invention concerne l'utilisation d'agonistes des récepteurs GLP-1, tels que le peptide-1 de type glucagon (GLP-1) ou l'exenatide, dans le traitement du cancer. Les agonistes des récepteurs GLP-1 sont typiquement administrés en utilisant un dispositif implanté d'administration osmotique permettant d'avoir une administration continue d'agonistes des récepteurs GLP-1 pendant au moins un mois. D'autres agents bénéfiques, tels que des agents anti-cancéreux, peuvent également être administrés.
지정국: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
공개언어: English (EN)
출원언어: English (EN)